Archive for the ‘Research’ Category

Thursday November 17th, 2016

Clinic-IDIBAPS researchers identify that the epigenetic history of lymphoma predicts its clinical course

A study published in the journal Cancer Cell  deciphers for the first time the epigenome of mantle cell lymphoma, an aggressive type of cancer derived from B lymphocytes, the cells of the immune system responsible for producing antibodies. The research reveals in detail the epigenetic history of lymphoma. On the one hand, it identifies the cell of origin and, on the other, it reveals that the more the epigenome of tumor cells evolves, the more aggressive the patient’s clinical course is. In addition, researchers discover that three-dimensional DNA conformation changes in lymphomas and leads to the activation of cancer genes. Dr. Iñaki Martín-Subero has coordinated the study. He is researcher at the University of Barcelona and at the Molecular Mechanisms of Lymphoid Neoplasms IDIBAPS research group, led by Dr. Elías Campo.

Read the rest of this entry »

Comments Closed
Wednesday November 16th, 2016

New gene-editing technology partially restores vision in blind animals

Salk Institute researchers, in collaboration, among others, with researchers from Hospital Clínic-IDIBAPS and the Universidad Católica San Antonio  de Murcia, have discovered a holy grail  for gene editing: the ability to, for the first time, insert DNA at a target location into the non-dividing cells that make up the majority of adult organs and tissuess. The technique, which the team showed was able to partially restore visual responses in blind rodents, will open new avenues for basic research and a variety of treatments, such as for retinal, heart and neurological diseases. The study, led by Dr. Juan Carlos Izpisúa-Belmonte, a professor in Salk’s Gene Expression Laboratory, has been published today in the journal Nature.

Read the rest of this entry »

Comments Closed

Categories

Posted in:

Tuesday September 27th, 2016

IDIBAPS researchers identify a new therapeutic target for liver cancer

IDIBAPS researchers have identified the first epi-driver in liver cancer, a type of epigenetic alteration in the IGF2 gene that causes tumors to grow. In the study, published in the Gastroenterology journal, they have found that this alteration occurs in 15% of tumors and that a monoclonal antibody can effectively block it and slow tumor progression in animal models. Dr. Josep M. Llovet, ICREA Professor, Head of the Translational research in hepatic oncology IDIBAPS group and Director of the Mount Sinai Liver Cancer Program at Icahn School of Medicine at Mount Sinai (New York), has coordinated this study. The first authors of the article are Iris Martínez-Quetglas and Roser Pinyol, researchers at the same team.

Read the rest of this entry »

Comments Closed
Friday September 16th, 2016

IDIBAPS shares one milion euros to develop a project on Multiple Sclerosis

Neuroscientist Elena H. Martínez-Lapiscina, researcher of the IDIBAPS, shares with other XXXX experts a million euros that the Grant for Multiple Sclerosis Innovation (GMSI) award to the best translational research projects which contribute to increase or improve the knowledge on Multiple Sclerosis ( MS) and the development of new therapies. Dr. Elena H. Martínez-Lapiscina project, presented at the ECTRIMS congress (European Comitee for Treatment and Research in Multiple Sclerosis ), aims to give a boost to the understanding of the disease and the developement of therapies through the analysis of the retina of affected patients.

Read the rest of this entry »

Comments Closed
Tuesday August 30th, 2016

Clínic takes part in the largest study describing the involvement of cardiovascular diseases in familial hypercholesterolemia

The journal Arteriosclerosis, Thrombosis and Vascular Biology ( ATVB ) has published the largest study describing the prevalence of premature Atherosclerosis and Cardiovascular Diseases (ASCVD ) in patients with Familial Hypercholesterolemia (FH) . Hospital Clínic is the largest contributor to this work with the participation of Dr. Daniel Zambón Rados, principal investigator in the Study SAFEHEART in Hospital Clínic and consultant of Lipids Unit of the Endocrinology and NutritionDepartment.

Read the rest of this entry »

Comments Closed
Thursday August 25th, 2016

New method creates for the first time kidney progenitor cells that survive in the lab

Salk scientists, in collaboration with Dr. Josep Maria Campistol, CEO and nephrologist of Hospital Clínic and Marta Lazo, IDIBAPS researcher, have managed to create and maintain renal structures through the use of a 3D culture and a new combination of signaling molecules. It is the first time that researchers succeed in maintaining a culture of Nephron Progenitor Cells (NPCs), which is an important boost to translational medicine and to research on the development of kidney disease and a further step towards the possibility of creating a transplantable kidney . The study, led by Dr. Juan Carlos Izpisua Belmonte, professor in Salk’s Gene Expression Laboratory, has been published in the journal Cell Stem Cell.

Read the rest of this entry »

Comments Closed
Page 5 of 52« First...34567...Last »